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Abstract
Background: Hemodiafiltration with on-line endogenous reinfusion (HFR) is an extracorporeal dialytic method that
combines diffusion, convection and adsorption. HFR-Supra (HFR-S) is a second-generation system with increased
convective permeability and adsorption capability. Previous studies suggested that HFR reduces oxidative stress
compared to standard haemodialysis. The principal aim of the present study was to compare antioxidant vitamins
behavior and oxidative status of hemodialysis patients treated with HFR and HFR-S.
Methods: The study was designed as a multicenter, randomized, crossover trial. Forty-one patients were recruited
from 19 dialysis centers and after a 4-month washout stabilization period in on-line hemodiafiltration (ol-HDF), each
patient was randomized to a sequence of treatments (HFR-S followed by HFR or viceversa) with each treatment
applied over 6 months. Plasma levels of Advanced Oxidation Protein Products, Total Antioxidant Status, vitamins C,
A and E and their ligands (Retinol Binding Protein and total lipids) were measured at baseline and at the end of
each treatment period.
Results: Results show that the higher convective permeability of HFR-S with respect to HFR did not produce
additional beneficial effects on the patients’ oxidative status, a slight decrease of both Vitamin A and Retinol
Binding Protein being the only difference registered in the long-term. However, as compared to ol-HDF, both the
re-infusive techniques allowed to reduce the intradialytic loss of Vitamin C and, in the long-term, improve the
patients’ oxidative status and increase Retinol Binding Protein plasma values. No significant differences were found
between the Vitamin C concentration of pre- and post cartridge UF neither in HFR-S nor in HFR showing that the
sorbent resin does not adsorb Vitamin C.
Conclusion: HFR-S and HFR are almost equivalent in term of impact on antioxidant vitamins and oxidative status of
hemodialysis patients. Nonetheless, as compared to ol-HDF, both treatments produced a sensible sparing of Vitamin C
and may represent a new approach for reducing oxidative stress and related complications in dialysis patients. Long-
term effects of re-infusive treatments on patients’ cardiovascular morbidity and mortality need to be evaluated.
Trial registration: ClinicalTrials.gov Identifier NCT01492491, retrospectively registered in 10 December 2011.
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Background
Oxidative stress and inflammation are common occur-
rences in end stage renal disease (ESRD) and are believed
to play an important role in the excess cardiovascular
morbidity and mortality of these patients [1]. Oxidative
stress in ESRD is due to both enhanced oxidative capacity
and reduced antioxidant defenses, the latter including
impaired enzyme activities and decreased levels of antioxi-
dant vitamins [1–3]. Vitamin deficiencies in ESRD may
originate from diet restriction, reduced absorption by med-
ications and co-morbidities, uremia-related alterations of
metabolic pathways and intradialytic losses [3]. Vitamin C
(Vit C) is the most abundant and effective water-soluble
antioxidant in human plasma. Vit. C deficiency is very
common in dialysis patients mainly because of low dietary
intake, losses during dialysis and accelerated catabolism
[4–6]. Low levels of Vit C may have clinical consequences
and associations with increased cardiovascular morbidity
and mortality have been found [7, 8]. Vitamin E (Vit E)
and Vitamin A (Vit A) are two fat-soluble plasma antioxi-
dants and are transported in plasma by lipoproteins
and retinol binding protein (RBP), respectively. Although
inconsistent levels of Vit E levels have been reported in
uremic patients [3], the administration of this vitamin has
been suggested as a promising therapeutic strategy to limit
both oxidative stress and its clinical consequences in
hemodialysis patients; however, results obtained to date
are contradictory [3, 9, 10]. Vit. A levels are generally
increased in ESRD patients, mainly due to homeostatic
dysregulation of its plasma carrier, the retinol binding pro-
tein (RBP) [3, 11]. Nonetheless, in ESRD patients relatively
higher Vit. A concentrations are associated with a survival
advantage [12, 13]. The molecular mechanisms underlying
such an association have not yet been elucidated, albeit a
role in the inhibition of inflammatory response has been
hypothesized [12].
The enhanced oxidative capacity in uremia is due, at
least in part, to systemic microinflammation and up-
regulation of superoxide-producing enzymes [1]. This
chronic condition results in structural modification of
many plasma components, mainly protein and lipids
[14]. These modified molecules, even of large size, might
themselves become pro-inflammatory so ultimately leading
to a further increase of oxidative stress. The removal of
large uremic solutes, by breaking this vicious cycle, can
therefore contribute to decrease oxidative stress in ESRD.
It is known that large-size uremic solutes can more effi-
ciently be removed by convective dialysis modalities, such
as haemodiafiltration (HDF), than by standard haemodialy-
sis (HD). On-line HDF (ol-HDF), performed using high-
flux biocompatible membrane and high-quality ultrapure
dialysate, has been reported to provide superior reduction
in inflammation and oxidative stress than high-flux HD
[15, 16]. However, convective techniques may also cause
negative effects, including the loss of water-soluble antioxi-
dants and amino acids, which cannot be replaced by rein-
fusion of the dialysate. In particular, it has been calculated
that convective transport in ol-HDF is responsible of one-
third of Vit. C loss during dialysis, so limiting the advan-
tages of this techniques in decreasing oxidative stress [6].
Hemodiafiltration with endogenous reinfusion (HFR)
is a kind of HDF that utilizes separated convection, dif-
fusion and adsorption (Fig. 1) [17]. The system consist
of a two-stage filter to separate convection from diffu-
sion, combined with a sorbent cartridge to regenerate
blood ultrafiltrate (UF). The regenerated ultrafiltrate, ie
the plasmatic water deprived of those compounds which
had bound to the sorbent resin, is reinfused back to the
Fig. 1 Schematic representation of HFR
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patient between the first and second stage of the filter.
The sorbent cartridge contains styrene divinylbenzene
(SDVB) hydrophobic resin which has a high affinity for
different uremic toxins, cytokines and inflammatory
mediators [18–21] while it does not retain nutrients
like albumin and amino acids [22–24]. Hence, this
technique allows the removal of medium/large uremic
solutes by avoiding at the same time the loss of important
nutrients. Previous studies showed that HFR has a better
impact on both inflammation and oxidative stress than
HD [25–28], with an efficacy similar to that of ol-HDF in
the long-term reduction of inflammatory markers [29].
Notably, HFR architecture permits to increase convective
membrane permeability up to a level which, due to the
risk of severe nutrients losses and consequent malnutri-
tion, is not achievable with standard HDF techniques. In
the new HFR SUPRA (HFR-S) configuration, the perme-
ability of the first convective chamber was incremented
with a new polyethersulfone (PES) hyper high-flux mem-
brane, Synclear 0.2 (Table 1). Uf proteomic analysis
showed that Synclear 0.2, as compared to a PES high-flux
membrane, allows a better extraction of middle-high mo-
lecular weight solutes and protein bound uremic toxins
[30, 31]. Based on all the above, one can thus hypothesize
that the increased depurative capacity of HFR-S might
have a positive impact on the oxidative status of dialysis
patients. The present study was designed to verify this
hypothesis by comparing HFR and HFR-S treatments as
for their short- and long-term effects on plasma levels of
Advanced Protein Oxidation Products (AOPP), Total
Antioxidant Status (TAS) and antioxidant vitamins C, A,
E and their ligands (Retinol Binding Protein, RBP, and
total lipids for Vit A and E, respectively). Moreover, since
the UF re-infusion would allow sparing (micro)nutrients
such as Vit C thereby potentially beneficial effects on pa-
tients (anti)oxidative status are produced, a secondary aim
of the study was to compare the two re-infusive tech-
niques with the ol-HDF, used in the run-in phase.
Finally, we evaluated the sieving coefficient (SC-like)
of vit C through the convective membranes and its ad-
sorption on the SDVB resin cartridges at both the start
and the end of HFR-S and HFR single sessions.
Methods
Study design and participant characteristics
The study was designed as a prospective, multicenter,
crossover trial with centralized randomization (Fig. 2).
Between July and December 2011, forty-one ESRD pa-
tients were recruited from 19 territorial Dialysis Units of
the National Public Health Care Service of Sardinia
(Italy); their mean age was 67.0 ± 14.2 years (min 21, max
86); mean dialysis vintage was 101.8 ± 82.2 months. The
total duration of the study was 16 months: after a 4-
month run-in period in post-dilution ol-HDF by a hollow-
fiber dialyzers (PHYLTHER, Bellco S.r.l., Mirandola, Italy)
with 1.7 m2 PES HF membrane, each patient was random-
ized to a sequence of treatments (HFR-S followed by HFR
or viceversa) with each treatment applied over 6 months.
The randomization procedure was stratified by Center.
Twenty-nine patients completed the study: two patients
withdrew during the run-in period, further seven and
three patients during the first and second treatment
period, respectively (Fig. 2). Due to the earthquake that
struck Mirandola district in 2012, some logistical prob-
lems arose in properly storing the plasma aliquots for
AOPP an TAS measurements collected at the end of the
second treatment period. Hence, only the values up to the
first treatment period are available for these variables.




Membrane Type (surface) convective PES HF (0.7 m2) PES HHF (0.7 m2)
Sterilization mode:
gamma rays
diffusive PES LF (1.7 m2) PES LF (1.7 m2)










SDVB (40 mL) SDVB (80 mL)
PES Polyethersulfone (LF Low flux, HF high flux, HHF Hyper high flux)
SDVB Styrene Divinylbenzene
aBovin Serum Albumin
Fig. 2 Study flow-chart
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Inclusion criteria were dialysis vintage longer than
6 months, age > 18 years and well functioning vascular
access without recirculation (Qb ≥ 300 mL/min). Exclusion
criteria were: residual diuresis > 300 mL/day; significant
acute or chronic inflammatory comorbidities; non-renal re-
lated anemia; alcohol or drugs abuse; malignant neoplasms;
hemoglobinopathy or mielopathy; pregnancy. The causes
of ESRD were diabetes (21 %), glomerulonephritis (16 %),
interstitial nephrits (9 %), angionephrosclerosis (30 %),
polycystic kidney disease (5 %), undeterminated etiology
nature (19 %). The majority of patients followed a drug
regimen for the control of blood pressure, anemia and sec-
ondary hyperparathyroidism. All the subjects were warned
to avoid antioxidant supplements thorough all the study.
The extracorporeal dialysis treatment was performed
three times per week. All 19 participating Centers made
use of ultrapure, sterile and pyrogen-free dialysis solutions
checked once monthly by cultural and endotoxins con-
firmation. Dialysate fluids were produced by a bi-osmosis
and purified by daily nocturnal thermal disinfection of the
piping (≥90 °C) [32–34].
Preparation of collection tubes for Vit C analysis
To prevent the ex vivo degradation of Vit C, a reducing
agent (dithioerythritol, DTE, 10 mmol/L final concentra-
tion in blood) was added in advance to the collection
tubes. 10X DTE in physiological saline solution was pre-
pared just before use, made sterile by filtration (0.22 μm
pore size) and added to the tubes for blood and UF with-
drawal (0.3 mL for each 3 mL heparinised gel-containing
vacutainer and 0.2 mL for each 2 mL amber microcen-
trifuge tube, respectively). An insulin syringe was used
to preserve the vacutainer void. The entire procedure
was performed in a sterile environment and was highly
reproducible (CV = 1.6 %). The tubes with the additive
were stored at 4 °C until use (max 30 days). Preliminary
experiments showed that the amount of DTE added did
not affected blood cells integrity nor blood rheology up to
at least 60 min from the collection, effectively preserving
the Vit C content of either plasma or UF up to at least
90 days when specimens were stored at −25 °C [35].
Blood and UF sampling and processing
Blood and pre- and post-cartridge UF samples were col-
lected at any time of the study concomitantly with routine
blood tests, both at the beginning and at the end of a first
weekly dialysis session. Blood was collected in heparin gel-
containing tubes (for vitamins’ assays) and EDTA tubes (for
RBP, AOPP and TAS assays) and centrifuged within 30 min
from the collection. Gel-containing centrifuged tubes, sepa-
rated EDTA plasma and UF samples were then immediately
frozen (−20 °C). Within 10 days from the collection, the
samples were transferred in dry ice to the laboratory where
they were stored at −80 °C until analysis (30 days max).
AOPP and TAS assays
Plasma AOPP levels were measured by spectrophotom-
etry on a microplate reader (Bio-Rad 680 XR, Hercules,
CA, USA) calibrated with chloramine-T solutions (Sigma-
Aldrich, Saint Louis, MO, USA) in the presence of potas-
sium iodide [36]. Absorbance of the reaction mixture was
read at 340 nm against a blank solution. Results were
expressed as μmol/L of chloramine-T equivalents.
Plasma TAS levels were measured by a commercial
colorimetric assay (TAS Randox, County Antrim, UK).
Vit.s C, A, E assays
The determination of Vits C, A and E was carried out by
reverse-phase high performance liquid chromatography
(Varian model 9010, Varian Medical Systems, Palo Alto,
CA, USA) with UV and FL detection, according to previ-
ously published methods with some modifications [37,
38]. For Vit C assay, plasma and UF aliquots were ex-
tracted with an equal volume of 10 % metaphosphoric
acid and the acidic extracts were then separated on a
Synergy Polar-RP column (150 mm × 4.6 mm, 4 μm par-
ticle size, Phenomenex, Torrance, CA, USA), using
50 mM potassium phosphate buffer at pH 2.5 as mobile
phase. For vit.s A and E assay, plasma aliquots were sup-
plemented with the internal standard (6 μmol/L retinyl
acetate) and extracted with an equal volume of a mixture
of ethyl acetate-butanol (1:1). The separation of organic
extracts was then performed on a fully end-capped C18
(150 mm× 4.6 mm, 5 μm particle size, Spherisorb ODS2,
Waters Corporation, Milford, MA, USA) using 100 %
methanol as mobile phase. Chromatographic runs were
performed isocratically at a flow rate of 1.0 mL/min and
the column temperature was kept constant at 28 °C.
The eluted compounds were detected spectrophoto-
metrically at 245 nm (Vit C), 292 nm (Vit E) and
325 nm (retinyl acetate) and fluorometrically at 325 nm/
475 nm excitation/emission wavelengths (Vit A and reti-
nyl acetate). Chromatograms were analysed by the
Galaxie Chromatography Workstation software (version
1.9, Varian Inc.). Sample concentrations were calculated
from peak areas by a linear calibration model. The limits
of detection, calculated as the analyte concentration cor-
responding to a signal-to-noise (S/N) ratio of 3, were
0.6 μmol/L, 0.1 μmol/L and 2 μmol/L for Vits C, A and
E, respectively. A correction factor was applied to Vit C
results to correct for dilution by DTE. The chemicals
used were of the highest purity available (Sigma-Aldrich)
and the water was ultrapure (Milli-Q water filtration sys-
tem, Millipore Spa, Rome, Italy).
RBP and total lipids assays
Plasma RBP was determined by a commercial nephelo-
metric assay (BNII, Siemens Healthcare Diagnostics,
Tarrytown, NY, USA). Cholesterol and triglycerides were
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determined by local clinical chemistry laboratories by
means of commercial enzymatic methods. Total lipids
were calculated as the sum of cholesterol and triglycerides.
Data analysis
The statistical power was verified by the Authors and
Biostatistic Specialist of Ethic Committee. All blood
values at the end of the dialysis session were corrected
for hemoconcentration. Results are expressed as means
and standard deviations - or medians and interquartile
range depending on the distribution’s normality - for
continuous data and as frequency for categorical data. The
assumption of normality was checked by the Shapiro-
Wilk test. Vitamin levels below the method LOD were
assigned a value of ½ LOD. For all the variables but AOPP
and TAS, the long-term effects of the treatments were
compared by either CROS-analysis [39] (HFR-S vs HFR)
or repeated measures ANOVA (HFR vs HFR-S vs run-in)
using either parametric or non-parametric tests as appro-
priate. For AOPP and TAS, paired and unpaired t-test (or,
when appropriate, their non-parametric equivalents) were
used for comparison within arms and between arms, re-
spectively. As for the acute effects, the percent reduction
ratios (RR% = [start session value – end session value]
*100/start session value) of the different treatments were
compared by either ANOVA or ANCOVA, the latter be-
ing used in case of significant correlation between pre-
dialysis levels and intra-dialytic losses. Only values ≥ LOD
were entered into RR% calculation. Associations were
assessed by Spearman rank correlation test. Extreme out-
liers (more than 3 inter-quartile ranges) were excluded
from the statistical tests. P < 0.05 were considered signifi-
cant and all tests were 2-tailed. Statistical analysis and data
plotting were performed by using SigmaPlot ® 12.0 (Systat
Software Inc.).
Results and discussion
Patient demographics and clinical characteristics at baseline
are reported in Table 2. Study arms were well balanced and
no significant biases were introduced by study dropouts at
any time (data not shown). The operating conditions and
adequacy parameters of the different extracorporeal treat-
ments adopted in the study are reported in Table 3.
Patients’ biochemical data at the end of the run-in and
of each treatment period are reported in Table 4. At the
end of the run-in, most of the patients had low Vit. C,
high Vit. A and normal Vit. E levels; RBP values were also
higher than in non-uremic subjects resulting in lower-
than-normal Vit. A/RBP molar ratios; AOPP values were
in the normal range, while TAS values were higher-than-
normal. For all parameters but AOPP, the levels we found
were in agreement with those previously reported for
uremic subjects [3, 8, 11, 40–42]. At difference, AOPP
levels were significantly lower than it was previously
reported for these patients [36]. Although this discrepancy
could be due, at least in part, to the lack of standardized
measurements for AOPP [43], this result suggests that our
cohort was characterized by a low level of oxidative dam-
age at baseline. Given that a significant association has
been reported between malnutrition and oxidative stress
in ESRD [44], the above evidence is in good agreement
with and could be partially explained by the good nutri-
tional status of enrolled patients (Table 2). Moreover, the
use in all the participating centers of ultrapure dialysate
locally produced by biosmosis could also have played a
role in decreasing dialysis-related oxidative stress in our
patients’ cohort [45].
Table 2 Personal and clinical data of patients at enrollment
All Arm A Arm B
n 41 21 20
Age (years) 70 (61–76) 73 (56–79) 67 (65–73)
Dialysis vintage (months) 69 (35–153) 107 (53–164) 60 (29–135)
Gender M = 26 (63 %) M = 12 (57 %) M = 14 (70 %)
F = 15 (37 %) F = 9 (43 %) F = 6 (30 %)
Albumin (mg/dL) 3.6 (3.4–3.9) 3.6 (3.4–4.0) 3.7 (3.5–3.9)
Mean Body weight (kg) M = 63.5 ± 9.6 M = 63.2 ± 7.9 M= 63.8 ± 11.2
F = 56.5 ± 10.5 F = 53.6 ± 10.2 F = 60.7 ± 10.2
BMI M = 23.7 ± 3.4 M = 24.1 ± 2.3 M = 23.3 ± 4.2
F = 23.8 ± 4.4 F = 23.0 ± 4.1 F = 25.0 ± 4.8
Cardiovascular disease 59 % 62 % 55 %
Hypertension 78 % 81 % 75 %
Diabetes 22 % 19 % 25 %
Charlson Comorbidity
Score
6 (6–7) 6 (5–7) 6 (6–7)
Previous dialysis
treatment
BHD= 15 (37 %) BHD= 8 (38 %) BHD= 7 (35 %)
HDF = 10 (24 %) HDF = 4 (19 %) HDF = 6 (30 %)
HFR = 16 (39 %) HFR = 9 (43 %) HFR = 7 (35 %)
Continuous data are expressed either as mean ± SD or, in case of not normally
distributed data, as median (IQR)
Table 3 Operating conditions and adequacy parameters of the
different dialysis treatments adopted in the study
ol-HDF (run-in) HFR-S HFR
Session length (min) 233 ± 18 235 ± 25 233 ± 16
Qb (mL/min) 313 ± 31 312 ± 31 301 ± 32
Qd (mL/min) 500 500 500
Body weight loss (kg/session) 2.8 ± 0.8 2.7 ± 1.1 2.8 ± 0.9
(Re)infusion volume (L/session) 14.9 ± 2.5 12.9 ± 2.9 13.4 ± 4.1
(Re)infusion rate (mL/min) 64.2 ± 9.6 54.9 ± 13.4 57.5 ± 13.2
eqKt/V 1.22 ± 0.25 1.17 ± 0.32 1.12 ± 0.23
ePCR (g/Kg/day) 1.4 ± 0.6 1.07 ± 0.54 1.08 ± 0.35
Data are expressed as mean ± SD (n = 41, 50 and 50 for ol-HDF, HFR-S and
HFR, respectively)
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At the end of the study, no significant differences were
found between HFR-S and HFR as for their long-term ef-
fects on Vit C, Vit E, Vit E/lipids, AOPP and TAS levels
(Table 4). At difference, significantly lower levels of Vit A
and of its plasma carrier, RBP, were measured after HFR-S
than after HFR, the Vit A/RBP ratio being not significantly
different between the two treatments (Table 4, superscript
asterisks). Accordingly, in the short-term, the only signifi-
cant difference between HFR-S and HFR was the RBP
RR% which was higher in HFR-S (Fig. 3). The present re-
sults suggest that HFR-S and HFR are equivalent in terms
of effects on patients’ oxidative status. The modest differ-
ence in Vit A plasma levels did not significantly affect the
plasma antioxidant capacity and is easily explained by the
difference in the convective permeabilities of the two tech-
niques: the higher convective permeability of HFR-S facili-
tates the removal of both RBP (MW= 21.2 kDa) and RBP/
Vit A complexes from plasma leading to the decrease of
the circulating levels of both the protein and its ligand. In
fact, at difference of healthy subjects in whom virtually
all Vit. A/RBP complexes are bound to prealbumin so
preventing the renal loss of this vitamin, Vit. A/RBP
complexes unbound to prealbumin are significantly in-
creased in ESRD [40], allowing Vit. A passage trough
high-flux membranes and its loss in the outflow dialysate.
The evidence that the Vit A /RBP ratio was unchanged
between the two treatments substantiates the above
interpretation.
It has been demonstrated that the removal of middle-
large uremic solutes by convective techniques contribute
to decrease oxidative stress in haemodialysis patients [16].
Thus, we can conclude that the beneficial effects on oxi-
dative stress produced by using high-flux membranes in
HFR are not significantly improved by using hyper high-
flux membranes in HFR-S, ie by further increasing the
convective permeability. It could be argued that the low
starting levels of AOPP might have decreased the power
of the present study and that a higher number of subjects
as well as a longer observation period would allow signifi-
cant differences between HFR and HFR-S to emerge. Al-
though we cannot rule out this possibility, the evidence
that AOPP levels significantly decreased during the course
of both HFR-S and HFR without significant differences
between the two treatments (Table 4, superscript letters)
makes this hypothesis unlikely. In fact, as compared to the
values reached at the end of the run-in, both treatments
induced a significant decrease of both AOPP and TAS
and an increase of RBP (but not of vit. A) levels (Table 4,
superscript letters). These long-term changes cannot be
merely explained by differences in AOPP, TAS and RBP
RR%s: actually, the RR%s measured during the run-in ses-
sions (ol-HDF) were similar to those measured during
HFR-S and HFR sessions, with the sole exception of RBP,
whose RR% was significantly lower in HFR than in either
HFR-S or ol-HDF, without significant differences between
ol-HDF and HFR-S (Fig. 3). Thus, since RBP levels in-
creased over time during both HFR and HFR-S treat-
ments, it is unlikely that the differences in RR%s play a
Table 4 Pre-dialysis levels of antioxidant vitamins and oxidative
stress biomarkers at the end of run-in and of either HFR-S or
HFR treatments
End of run-in End of HFR-S End of HFR
Vitamin C (μmol/L) 20.0 (11–32) 21.5 (12–43) 20.0 (10–31)
Vitamin A (μmol/L) 2.8 ± 1.4 2.6 ± 1.0a 3.0 ± 1.2
Vitamin E (μmol/L) 20.2 ± 5.2 20.9 ± 5.9 20.9 ± 5.7
RBP (μmol/L) 5.8 ± 1.4 6.5 ± 1.6a, b 6.9 ± 1.6b
Total lipids (mmol/L) 5.6 ± 1.2 6.1 ± 1.7 6.3 ± 1.7
Vitamin A/RBP (μmol/μmol) 0.47 ± 0.17 0.40 ± 0.11b 0.42 ± 0.13c
Vitamin E/lipids (μmol/mmol) 3.6 ± 0.7 3.6 ± 0. 9 3.4 ± 0.8
AOPP (μmol/L) 28.4 (25–37) 21.7 (20–26)d -
35.8 (24–45) - 27.3 (21–34)d
TAS (mmol/L) 1.88 (1.7–2.2) 1.41 (1.3–1.6)d -
1.99 (1.8–2.2) - 1.43 (1.4–1.5)d
For all parameters but AOPP and TAS, only patients who completed the study
were included in the analysis and cumulative data of the two treatment
periods in HFR-S/HFR are represented. For AOPP and TAS only data of the first
treatment period were available, hence all patients who reached this stage
of the study were included in the analysis. Data are expressed either as
mean ± SD or, in case of not normally distributed data, as median (IQR)
a = p < 0.05 vs HFR, n = 29, Cross-analysis [39]
b = p < 0.01 and c = p < 0.05 vs End of run-in, n = 29, ANOVA for
repeated measures
d = p < 0.01 vs End of run-in, n = 14 (HFR-S) or 16 (HFR), Wilcoxon Signed
Rank Test
Fig. 3 Reduction ratios of the studied variables at the end of ol-HDF
(n = 41), HFR-S (n = 50) and HFR (n = 50) dialysis sessions. For AOPP
and TAS the numbers of studied sessions are 30, 28 and 32 for ol-HDF,
HFR-S and HFR, respectively. Each dialysis session at each time of the
study was included in the analysis. Data are expressed as means ± SE
(error bar). * = p < 0.01 vs ol-HDF; # = p < 0.05 vs ol-HDF; ° = p < 0.01 vs
HFR-S; ANOVA (RBP, Vitamin A, Vitamin E) or ANCOVA (Vitamin C,
TAS, AOPP)
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significant role in this phenomenon. Instead, the above re-
sults suggest that, as compared to ol-HDF, during both
the re-infusive treatments an homeostatic response took
place, consisting of 1) a progressive reduction of systemic
oxidative stress accompanied by an adaptative reduction
of the plasma antioxidant potential, and 2) an increase of
RBP circulating levels.
In our study, ol-HDF, HFR-S and HFR used the same
machines, same ultrapure dialysate and same PES
membranes, although that used in HFR-S had a higher
convective permeability (see Table 1). Thus, in our study
the main difference between ol-HDF and HFR-S/HFR
consisted in the UF re-infusion. The re-infusion solution
is the same plasmatic water of the patient purified on the
sorbent cartridge; the composition of this solution de-
pends on the sorbent adsorption capability which is virtu-
ally zero with respect to albumin and amino acids and
significantly different from zero with respect to some
uremic toxins and inflammatory citokines [18–24]. In the
present study we show for the first time that the sorbent
cartridge does not significantly adsorb Vit. C, since no sig-
nificant differences were found between the Vit.C concen-
tration of pre- and post cartridge UF neither in HFR-S nor
in HFR (ns Wilcoxon Signed Rank Test, n = 22 and
26, respectively, Fig. 4). That means that the ultrafiltered
Vit C can be entirely returned to the circuit, thereby its
intra-dialytic loss is reduced. It has been reported that
during a HDF session, both convective and diffusive losses
of Vit. C occur, both potentially contributing to the oxida-
tive stress in haemodialysis patients [6]. Accordingly, in
the present study we show that the two re-infusive tech-
niques allowed to reduce Vit C RR% by about 15 % as
compared to ol-HDF (Fig. 3). Despite the sparing effect
produced by each HFR-S/HFR session, we did not find
any significant long term increase of Vit. C levels during
the treatments (Table 4). This may be due, at least in part,
to the high intra- and inter-subject variability of the
plasma levels of this vitamin. Nonetheless, it cannot be
ruled out that the sparing of Vit. C – and possibly of other
small hydrophilic plasma components endowed with anti-
oxidant/nutritional properties – may have played a role in
the long-term improvement of oxidative status produced
by the two re-infusive treatments.
As for RBP, the present results suggest that, as com-
pared to ol-HDF, both HFR-S and HFR activate endogen-
ous mechanisms of RBP plasma level modulation, likely
due to the stimulation of its de novo synthesis. The RBP
increase was not associated with a corresponding Vit. A
increase, resulting in a net reduction of the Vit. A/RBP ra-
tio (Table 4). This result was rather unexpected, since RBP
is physiologically secreted bound to retinol. However, in
uremic patients the retinol content of the liver is dramat-
ically reduced [46], thus giving a possible explanation for
the above result.
At this time we can only speculate about the biological
mechanisms underlying the observed increase of RBP
plasma levels. From a physiological point of view, RBP
behaves as a negative acute phase protein, ie both in-
flammation and protein malnutrition depress its hepatic
synthesis [47–50]. It is known that hemodialysis patients
are at higher risk of both inflammation and malnutrition,
a large part of them exhibiting an activated acute phase re-
sponse [51]. Hence, RBP increase might be a consequence
of an improvement of patient inflammatory/nutritional
status. A previous study did not find significant differences
between the circulating levels of some inflammatory
markers in HFR and ol-HDF, thus making this hypothesis
unlikely [29]. However, it is worth underlying that in the
present study RBP increase was accompanied by a signifi-
cant improvement of patients’ oxidative status and that
oxidative stress and inflammation share common patho-
genic mechanisms [52]. From a pathological point of view,
it should be taken into consideration that in ESRD free
RBP and Vit A/RBP complexes are chronically increased,
mainly due to the impairment of RBP renal catabolism
[11, 40]. Based on an experimental model of AKI, it has
been also proposed that a peripheral regulatory signal,
normally removed by the kidney, might accumulate in the
circulation and upregulate the hepatic release of Vit A/
RBP complexes [53]. Thus one can hypothesize that this
supposed regulatory signal accumulates in plasma of CKD
patients, from where it might be removed by convective
transport and, only in case of HFR(−S), be returned to the
patient by means of UF re-infusion. In such a way, the
stimulus to RBP hepatic release would be lower in ol-HDF
than in either HFR-S or HFR. Anyway, regardless of the
Fig. 4 Comparison between the vitamin C levels of pre- and post-
cartridge UFs during HFR-S and HFR dialysis sessions. Dotted
line = identity line
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mechanisms behind the RBP level increase, higher RBP
and Vit. A values in hemodialysis patients are associated
with a better prognosis, lower values - even still higher
than normal values - being strongly associated with higher
mortality and cardiovascular risk [12, 13]. With this in
mind and considering also that convective dialysis com-
pared to purely diffusive dialysis is supposed to reduce
cardiovascular mortality [54], further studies should be
undertaken to i) investigate on the long-term impact of
different convective techniques on patients’ survival and
cardiovascular risk, and ii) better define, if any, the dis-
tinctive roles of Vit. A and RBP in the phenomenon.
Finally, we found that, irrespective of the dialysis treat-
ment adopted, i) Vit. C levels were negatively related to
the patients’ age and positively related to the vit. A levels
(p < 0.01), and, as expected, ii) Vit.s A and E levels were
highly correlated to their respective plasma carriers, RBP
and total lipids (p < 0.001,Table 5). A strong negative as-
sociation between Vit. C and age in older people has
been previously reported for the general population [55].
Hence, it is likely that physiological mechanisms linked
to the elderly rather than to the kidney disease per se are
responsible for the above association. The strong associ-
ation between Vit. C and Vit. A is instead rather surpris-
ing since these vitamins are supposed to exert their
antioxidant activity in different biological environments;
in fact, while Vit. C is a water-soluble antioxidant, Vit. A is
a lipid-soluble antioxidant, being significantly less effective
than Vit. E in scavenging aqueous radicals [56]. In the
general population only a weak interaction was found be-
tween Vit. C and Vit. A while a stronger association was
found between Vit. C and Vit. E, likely explained by their
close physiological interaction [57]. At difference, in our
patients Vit. C was significantly related only to Vit. A. If
mechanisms other than radical scavenging mediate Vit. C/
Vit. A association in ESRD patients deserves further inves-
tigation and is beyond the aims of the present study.
Limitations of the present study were the relatively small
sample size, the ethnicity of enrolled patients (all from
Sardinia, an Italian island housing genetically homogenous
populations with traditional living habits) and the lack
of measurement of inflammation and uremic retention
biomarkers. Further studies overcoming the above limita-
tions will allow to strengthen and expand on the present
results.
Conclusion
Kidney failure is associated with oxidative stress.
Hemodialysis may contribute to increase oxidative stress
of ESRD patients due to the activation of inflammatory
pathways and to the loss of small water-soluble anti-
oxidants. Convective dialysis modalities can reduce
the burden of oxidative stress of hemodialysis patients
by allowing the removal of large pro-oxidant uremic
solutes from plasma. Unlike ol-HDF, which is a mixed
convective-diffusive method, HFR-S and HFR exploit in
sequence convection, adsorption and diffusion. Thanks to
the adsorption step, UF is purified by toxic molecules and
it can be re-infused to the patient. Since other UF compo-
nents such as albumin, amino acids and Vit C are not
adsorbed, HFR architecture allows to increase convective
permeability without the risk of losing useful substances.
In the present study, we show that the higher convective
permeability of HFR-S with respect to HFR did not pro-
duce additional beneficial effects on the oxidative status of
ESRD patients, the only significant difference being a
long-term decrease of Vit. A due to the more efficient re-
moval of its plasma carrier, RBP. Further studies are
needed to investigate whether the more efficient removal
of large molecules by HFR-S produces additional benefi-
cial effects over HFR in term of (micro)inflammation and
uremic toxins retention.
In comparison to ol-HDF, both the re-infusive techniques
allow to significantly reduce the intradialytic loss of Vit. C
and, in the long-term, improve the patients’ oxidative status
and increase RBP plasma values, all effects which might
have a potentially positive impact on patients’ cardiovascu-
lar morbidity and mortality.
Nutrient supplementation is often used to provide
malnourished haemodialysis patients with essential ami-
noacids, vitamins and minerals and/or to counteract the
loss of useful substances upon high-convection dialysis
techniques. HFR-S and HFR, by returning his own plas-
matic water back to the patient, can be a way to restore a
more physiological status without additional therapies.
Moreover, both the financial and technical costs of nutrient
supplementation make HFR definitely more advantageous
over other convective techniques with similar depurative
capacity. Finally, HFR architecture paves the way for
potential, further increase of convective permeability,
an improvement otherwise entailing severe loss of plasma
proteins which must then be restored by additional infu-
sional therapies.
Table 5 Significant results of bivariate correlation analysis of
antioxidant vitamins and oxidative stress biomarkers pre-dialysis
levels at the end of run-in and after a six-months treatment
period in HFR-S or HFR
End of run-in End of HFR-S End of HFR
Vitamin C vs age −0.626*** (31) −0.543** (30) −0.553** (30)
Vitamin C vs Vitamin A 0.476** (31) 0.529** (30) 0.510** (30)
Vitamin A vs RBP 0.841*** (32) 0.613*** (31) 0.616*** (30)
Vitamin E vs total lipids 0.689*** (31) 0.642*** (27) 0.639*** (27)
Analysed parameters included: age, dialysis vintage, Vit C, Vit A, Vit E, RBP,
total lipids, Vit A/RBP, Vit E/total lipids, AOPP, TAS. All patients that completed
at least the first treatment period were included in the analysis
Data are expressed as rs (n), Spearman correlation test
*p < 0.05; **p < 0.01, ***p < 0.001
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Ol-HDF has been reported to produce clinical and
survival benefits with respect to HD. Nonetheless ESRD
patients on convective dialysis still show high levels of
inflammation, oxidative stress and high cardiovascular
morbidity and mortality. HFR-S and HFR could repre-
sent a new biotechnological response potentially able to
reduce side effects and complications. The long-term
impact of these new techniques on patients’ survival and
cardiovascular risk need to be evaluated.
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